H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Y-Mabs Therapeutics (YMAB – Research Report) today and set a price target of $21.00.
Robert Burns has given his Buy rating due to a combination of factors surrounding Y-Mabs Therapeutics’ advances in the field of targeted radiotherapy. Notably, the company’s SADA technology is positioned to make radiotherapy both safer and more effective. By separating the tumor-targeting process from the delivery of the radioactive payload, SADA has demonstrated the potential for enhanced tumor uptake and minimized exposure to normal tissues. This system has shown promising preclinical dosimetry data, indicating a significant edge over other pre-targeting approaches in the radiopharmaceutical space.
Further bolstering the Buy recommendation, Y-Mabs’ GD2-SADA has exhibited strong binding affinity to its target antigen and demonstrated impressive results in vivo, with substantial uptake in GD2-expressing tumors and notable anti-tumor activity. The additional data expected this year is likely to reinforce the therapeutic’s potential. Moreover, the pharmacokinetics and imaging data of GD2-SADA suggest rapid uptake and clearance, alongside significant tumor localization and minimal off-tumor presence, which could translate into a favorable safety and efficacy profile for patients. These factors collectively underpin Burns’ positive outlook on the stock.
Burns covers the Healthcare sector, focusing on stocks such as BioNTech SE, Black Diamond Therapeutics, and Repare Therapeutics. According to TipRanks, Burns has an average return of -22.3% and a 24.40% success rate on recommended stocks.
In another report released on February 12, Wedbush also maintained a Buy rating on the stock with a $18.00 price target.
See the top stocks recommended by analysts >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Y-Mabs Therapeutics (YMAB) Company Description:
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company’s services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
Read More on YMAB:
